Clinical Trials Browser

Gynecological Cancer

NCT06062563 2023-10-02

Study of Anlotinib in Patients With Radioiodine Refractory Differentiated Thyroid Cancer

Phase NA Unknown

10 enrolled

EndocrineHead & Neck

Locally Advanced or Metastatic Radioiodine-refractory Differentiated Thyroid Carcinoma

NCT05885399 2023-06-02

The Efficacy and Safety of Penpulimab in the Treatment of Metastatic PPGL Patients Who Fail to Other Systemic Treatment

Phase 2 Unknown

5 enrolled

CNSEndocrine

Neoplasm Metastasis, Paraganglioma, Extra-Adrenal, Pheochromocytoma

NCT05726175 2023-02-13

Disitamab Vedotin(RC48) Combined With Penpulimab(AK105) for Neoadjuvant Treatment of HER2-low Breast Cancer

Phase 2 Unknown

20 enrolled

Breast

Breast Neoplasms

NCT05680038 2023-01-11

Penpulimab in Maintenance Therapy in Lymphoma

Unknown

167 enrolled

Lymphoid

Lymphoma

NCT05519202 2022-08-29

Exploratory Clinical Study of Penpulimab Combined With SOX in the Perioperative Treatment of Gastric Cancer

Phase 2 Unknown

47 enrolled

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

NCT05485350 2022-08-03

Anlotinib , Penpulimab Combined With SBRT for Metastatic Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Unknown

32 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05244993 2022-07-12

AK105 Plus Anlotinib Hydrochloride Combined With Albumin Paclitaxel as a First-line Therapy in Patients With Advanced Triple-negative Breast Cancer

Phase 2 Unknown

42 enrolled

Breast

Breast Neoplasm Female

NCT05319886 2022-05-20

AP

Unknown

40 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04970914 2022-03-08

ALTER-C003

Phase 2 Unknown

32 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT05186558 2022-03-07

Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL

Phase 2 Unknown

54 enrolled

Lymphoid

Neoplasms by Histologic Type, Lymphoma, Large B-Cell, Diffuse

NCT05265962 2022-03-04

Decitabine Plus Penpulimab as Second-line Therapy for Advanced ESCC Treated With PD-1 Blockade

Phase 2 Unknown

85 enrolled

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT04952493 2022-01-28

Anlotinib or Penpulimab in Combination With RAI for DTC

Phase 2 Unknown

42 enrolled

Head & Neck

Thyroid Neoplasms

NCT05137171 2021-11-30

AK105 Combined With Anlotinib in Patients With Cervical Cancer

Phase 2 Unknown

36 enrolled

Gynecologic

Uterine Cervical Neoplasms

Clinical Trials

ALTER-GO-020

Study of Anlotinib in Patients With Radioiodine Refractory Differentiated Thyroid Cancer

The Efficacy and Safety of Penpulimab in the Treatment of Metastatic PPGL Patients Who Fail to Other Systemic Treatment

Disitamab Vedotin(RC48) Combined With Penpulimab(AK105) for Neoadjuvant Treatment of HER2-low Breast Cancer

Penpulimab in Maintenance Therapy in Lymphoma

Exploratory Clinical Study of Penpulimab Combined With SOX in the Perioperative Treatment of Gastric Cancer

Anlotinib , Penpulimab Combined With SBRT for Metastatic Non-Small Cell Lung Cancer (NSCLC)

AK105 Plus Anlotinib Hydrochloride Combined With Albumin Paclitaxel as a First-line Therapy in Patients With Advanced Triple-negative Breast Cancer

AP

ALTER-C003

Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL

Decitabine Plus Penpulimab as Second-line Therapy for Advanced ESCC Treated With PD-1 Blockade

Anlotinib or Penpulimab in Combination With RAI for DTC

AK105 Combined With Anlotinib in Patients With Cervical Cancer